General Information of the Protein
Protein ID
PT01495
Protein Name
Protein kinase C beta type
Gene Name
PRKCB
Secondarily
Gene Name
PKCB
PRKCB1
Sequence
MADPAAGPPPSEGEESTVRFARKGALRQKNVHEVKNHKFTARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPASDDPRSKHKFKIHTYSSPTFCDHCGSLLYGLIHQGMKCDTCMMNVHKRCVMNVPSLCGTDHTERRGRIYIQAHIDRDVLIVLVRDAKNLVPMDPNGLSDPYVKLKLIPDPKSESKQKTKTIKCSLNPEWNETFRFQLKESDKDRRLSVEIWDWDLTSRNDFMGSLSFGISELQKASVDGWFKLLSQEEGEYFNVPVPPEGSEANEELRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMKLTDFNFLMVLGKGSFGKVMLSERKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPGKPPFLTQLHSCFQTMDRLYFVMEYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQSKGIIYRDLKLDNVMLDSEGHIKIADFGMCKENIWDGVTTKTFCGTPDYIAPEIIAYQPYGKSVDWWAFGVLLYEMLAGQAPFEGEDEDELFQSIMEHNVAYPKSMSKEAVAICKGLMTKHPGKRLGCGPEGERDIKEHAFFRYIDWEKLERKEIQPPYKPKARDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
AGC protein kinase group
>
AGC protein kinase PKC family
>
AGC protein kinase PKC alpha subfamily
Function
Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity (PubMed:11598012). Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. Participates in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 (PubMed:25982116). Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription (PubMed:19176525). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067).
    Show/Hide
Uniprot ID
Primary ID:
P05771

Secondarily ID:
C5IFJ8
D3DWF5
O43744
P05127
Q15138
Q93060
Q9UE49
Q9UE50
Q9UEH8
Q9UJ30
Q9UJ33
    Show/Hide
Ensembl ID
ENSG00000166501
HGNC ID
HGNC:9395
Subcellular Location
Cytoplasm
Nucleus
Membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000006 , HEK293
Compound ID Compound Name Compound Formula
CP0013045
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-quinolin-3-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C33H28N6O2
 1
1
IC50 = 20 nM
   TI
   LI
   LO
   TS
CP0008384
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C34H29N5O2
 1
1
IC50 = 24 nM
   TI
   LI
   LO
   TS
CP0027173
20-ethyl-17,23-dioxa-4,14,20,26-tetraazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H32N4O4
 1
1
IC50 = 25 nM
   TI
   LI
   LO
   TS
CP0089794
3-(1-{2-[2-(2-Dimethylamino-ethoxy)-ethoxy]-ethyl}-1H-indol-3-yl)-4-(1-propyl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C30H32N4O4
 1
1
IC50 = 45 nM
   TI
   LI
   LO
   TS
CP0129611
20,23-dimethyl-17-oxa-4,14,20,23,26-pentaazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H33N5O3
 1
1
IC50 = 46 nM
   TI
   LI
   LO
   TS
CP0129551
20-(2-hydroxyethyl)-17,23-dioxa-4,14,20,26-tetraazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H32N4O5
 1
1
IC50 = 58 nM
   TI
   LI
   LO
   TS
CP0167755
3-(1-Morpholin-2-yl-1H-indazol-3-yl)-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C36H31N5O3
 1
1
IC50 = 72 nM
   TI
   LI
   LO
   TS
CP0013222
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-thiophen-2-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C28H25N5O2S
 1
1
IC50 = 75 nM
   TI
   LI
   LO
   TS
CP0004106
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one
   Show/Hide
C28H26N4O3
 1
1
IC50 = 77 nM
   TI
   LI
   LO
   TS
CP0078259
17,20,23-trimethyl-4,14,17,20,23,26-hexaazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C31H36N6O2
 1
1
IC50 = 82 nM
   TI
   LI
   LO
   TS
CP0008485
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-pyridin-3-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C29H26N6O2
 1
1
IC50 = 82 nM
   TI
   LI
   LO
   TS
CP0102572
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-isoquinolin-4-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C33H28N6O2
 1
1
IC50 = 86 nM
   TI
   LI
   LO
   TS
CP0172361
3-[1-(1,2-Dihydro-pyridin-2-yl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C36H31N5O2
 1
1
IC50 = 170 nM
   TI
   LI
   LO
   TS
CP0005235
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-1-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C34H29N5O2
 1
1
IC50 = 600 nM
   TI
   LI
   LO
   TS
CP0005230
3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C32H27N5O2S
 1
1
IC50 = 630 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0004106
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one
   Show/Hide
C28H26N4O3
 10
1 IC50 = 1.44 nM
2 IC50 = 2.5 nM
3 IC50 = 2.78 nM
4 IC50 = 4 nM
5 IC50 = 7.26 nM
6 IC50 = 10 nM
7 IC50 = 12 nM
8 IC50 = 19 nM
9 IC50 = 23 nM
10 IC50 = 63 nM
CP0013045
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-quinolin-3-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C33H28N6O2
 2
1 IC50 = 4 nM
2 IC50 = 7 nM
CP0008384
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C34H29N5O2
 2
1 IC50 = 5 nM
2 IC50 = 33 nM
CP0008485
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-pyridin-3-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C29H26N6O2
 2
1 IC50 = 7 nM
2 IC50 = 19 nM
CP0027173
20-ethyl-17,23-dioxa-4,14,20,26-tetraazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H32N4O4
 2
1 IC50 = 9 nM
2 IC50 = 14 nM
CP0129611
20,23-dimethyl-17-oxa-4,14,20,23,26-pentaazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H33N5O3
 2
1 IC50 = 9 nM
2 IC50 = 10 nM
CP0040333
2-{[2,6-dihydroxy-4-({[(3R,4R)-4-[(4-hydroxybenzene)amido]pyrrolidin-3-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C26H22N2O10
 3
1 IC50 = 10 nM
2 IC50 = 17 nM
3 IC50 = 33 nM
CP0038373
2-{[2,6-dihydroxy-4-({[(3R,4R)-3-[(4-hydroxybenzene)amido]azepan-4-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C28H26N2O10
 6
1 IC50 = 10 nM
2 IC50 = 30 nM
3 IC50 = 32 nM
4 IC50 = 40 nM
5 IC50 = 44 nM
6 Kd = 1.8 nM
CP0013222
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-thiophen-2-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C28H25N5O2S
 2
1 IC50 = 10 nM
2 IC50 = 15 nM
CP0102572
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-(1-isoquinolin-4-yl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C33H28N6O2
 2
1 IC50 = 15 nM
2 IC50 = 92 nM
CP0167755
3-(1-Morpholin-2-yl-1H-indazol-3-yl)-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C36H31N5O3
 2
1 IC50 = 18 nM
2 IC50 = 190 nM
CP0078259
17,20,23-trimethyl-4,14,17,20,23,26-hexaazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C31H36N6O2
 2
1 IC50 = 27 nM
2 IC50 = 31 nM
CP0005235
3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-1-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C34H29N5O2
 2
1 IC50 = 29 nM
2 IC50 = 87 nM
CP0005230
3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C32H27N5O2S
 2
1 IC50 = 37 nM
2 IC50 = 86 nM
CP0040070
2-{[2,6-dihydroxy-4-({[(1R,2R)-2-[(4-hydroxybenzene)amido]cyclopentyl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
   Show/Hide
C27H23NO10
 2
1 IC50 = 40 nM
2 IC50 = 50 nM
CP0129551
20-(2-hydroxyethyl)-17,23-dioxa-4,14,20,26-tetraazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8(13),9,11,27(32),28,30-nonaene-3,5-dione
   Show/Hide
C30H32N4O5
 2
1 IC50 = 40 nM
2 IC50 = 68 nM
CP0172361
3-[1-(1,2-Dihydro-pyridin-2-yl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
   Show/Hide
C36H31N5O2
 2
1 IC50 = 44 nM
2 IC50 = 120 nM
CP0089794
3-(1-{2-[2-(2-Dimethylamino-ethoxy)-ethoxy]-ethyl}-1H-indol-3-yl)-4-(1-propyl-1H-indol-3-yl)-pyrrole-2,5-dione
   Show/Hide
C30H32N4O4
 2
1 IC50 = 46 nM
2 IC50 = 73 nM
Clinical Information about the Protein
Target 1 ( Protein kinase C beta (PRKCB) )
Target Type Clinical trial Target
Disease 3 Target-related Diseases  3
1 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
2 Non-hodgkin lymphoma [ICD-11: 2B33.5]
3 Human immunodeficiency virus infection [ICD-11: 1C62]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 LY333531 Phase 2
Solid tumour/cancer
2 Enzastaurin Phase 3
Non-hodgkin lymphoma
Investigative Drug(s) 1 Investigative Drug  1
1 PROSTRATIN Investigative
Human immunodeficiency virus infection